Cervical cancer · 13 regimens
Cost vs Efficacy · 1 point
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cisplatin, Pembrolizumab, RT Variant #02 | — | R 329 714 | 63d | — | — | ~3 | ~R 493 688 PFS proxy · indirect | 2 |
Cisplatin and Gemcitabine (GC) and RT Variant #01 | — | R 6 781 | 42d | — | — | ~1 | ~R 6 781 PFS proxy · indirect | 2 |
Fluorouracil, Mitomycin, RT Variant #01 | — | R 5 186 | 56d | — | ~18.9 mo | ~1 | ~R 5 186 PFS proxy · indirect | 1 |
Carboplatin and RT Variant #01 | — | R 3 746 | 42d | — | ~22.4 mo | ~1 | ~R 3 746 PFS proxy · indirect | 1 |
Cisplatin and Fluorouracil (CF) and RT Variant #01 | — | R 1 774 | 17d | — | — | ~1 | ~R 1 774 PFS proxy · indirect | 1 |
Cisplatin and Fluorouracil (CF) and Hydroxyurea, RT Variant #01 | — | R 1 337 | 42d | — | — | ~1 | ~R 1 337 indirect | — |
Fluorouracil and RT Variant #01 | — | R 809 | 42d | — | ~17.1 mo | ~1 | ~R 809 PFS proxy · indirect | 5 |
Cisplatin and RT Variant #01 | — | R 588 | 49d | ~28.0 mo | — | ~1 | ~R 588 PFS proxy · indirect | 8 |
Hydroxyurea and RT Variant #01 | — | R 406 | 63d | — | ~59.8 mo | ~1 | ~R 406 PFS proxy · indirect | — |
Brachytherapy protocol Partial | — | — | — | — | — | — | — | — |
Radiation therapy N/A - radiation | — | — | 49d | — | — | — | — | 3 |
Brachytherapy Partial | — | — | — | — | — | — | — | — |
Nedaplatin and RT Variant #01 Partial | — | — | — | ~30.0 mo | — | ~1 | — | 1 |
13 of 13 regimens shown